Business · Companies · 5 hrs ago
Alcon to buy Neurotech Pharmaceuticals for $550 million
Alcon is buying US biotech company Neurotech Pharmaceuticals for $550 million, with possible additional payments tied to results.
The Swiss eye-care company says the deal will add Encelto to its retina business.
Encelto is the first and only treatment approved in the United States for adults with MacTel type 2, a rare disease that causes progressive loss of central vision.
US regulators approved Encelto in March 2025.
Alcon says about 25,000 people in the United States have been diagnosed with MacTel, and 2,000 to 3,000 new diagnoses are made each year.
The deal is expected to slightly boost sales growth in 2027, while slightly reducing adjusted earnings per share that year; after that, Alcon expects it to increase earnings.
Alcon has acquired US biotech company Neurotech Pharmaceuticals for $550 million, with possible additional payments tied to performance.
The acquisition adds Encelto to Alcon’s retina business.
Encelto is the only treatment approved in the United States for adults with MacTel type 2, a rare retinal disease that causes progressive loss of central vision.
Alcon expects the deal to slightly increase revenue growth in 2027 and slightly reduce adjusted earnings per share that year, before becoming earnings-enhancing.
- Who
- Alcon acquired Neurotech Pharmaceuticals, a US biotech company.
- What
- Alcon agreed to pay $550 million, with possible additional performance-based payments.
- When
- The acquisition was announced on Tuesday, October 20, 2026.
- Where
- The companies are based in the United States; the deal adds a treatment approved in the United States to Alcon’s retina business.
- Why
- The acquisition expands Alcon’s retina business with Encelto, a treatment for MacTel type 2.
This story does not have two clearly opposing sides.
The US Food and Drug Administration approved Encelto.
Alcon announced its acquisition of Neurotech Pharmaceuticals.
- Purchase price
- $550 million
- Additional payments
- Possible, performance-based
- Added treatment
- Encelto
- US diagnosed MacTel patients
- About 25,000
- New US diagnoses
- 2,000 to 3,000 a year
- FDA approval
- March 2025